REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 219 filers reported holding REATA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $8,642,639 | +181.5% | 56,649 | +67.8% | 0.01% | +175.0% |
Q1 2023 | $3,069,823 | +175.9% | 33,764 | +15.3% | 0.00% | +100.0% |
Q4 2022 | $1,112,461 | -99.9% | 29,283 | -52.5% | 0.00% | 0.0% |
Q3 2022 | $1,549,265,000 | -37.8% | 61,650 | -24.8% | 0.00% | -50.0% |
Q2 2022 | $2,491,129,000 | +33.3% | 81,972 | +43.7% | 0.00% | +33.3% |
Q1 2022 | $1,868,434,000 | +105.7% | 57,034 | +65.6% | 0.00% | +200.0% |
Q4 2021 | $908,236,000 | -58.9% | 34,442 | +56.8% | 0.00% | -66.7% |
Q3 2021 | $2,209,295,000 | +161.5% | 21,959 | +267.8% | 0.00% | +200.0% |
Q2 2021 | $844,934,000 | +650.6% | 5,970 | +428.8% | 0.00% | – |
Q1 2021 | $112,561,000 | +13.7% | 1,129 | +40.9% | 0.00% | – |
Q4 2020 | $99,020,000 | +111.8% | 801 | +66.9% | 0.00% | – |
Q3 2020 | $46,762,000 | -95.6% | 480 | -93.0% | 0.00% | -100.0% |
Q2 2020 | $1,072,325,000 | -1.1% | 6,873 | -8.5% | 0.00% | 0.0% |
Q1 2020 | $1,084,282,000 | +67.2% | 7,512 | +136.8% | 0.00% | +100.0% |
Q4 2019 | $648,452,000 | +119.3% | 3,172 | -13.9% | 0.00% | 0.0% |
Q3 2019 | $295,628,000 | +22.3% | 3,682 | +43.8% | 0.00% | – |
Q2 2019 | $241,630,000 | -35.5% | 2,561 | -41.6% | 0.00% | -100.0% |
Q1 2019 | $374,786,000 | +3653.1% | 4,385 | +2363.5% | 0.00% | – |
Q4 2018 | $9,986,000 | -84.1% | 178 | -76.8% | 0.00% | – |
Q3 2018 | $62,710,000 | +207.6% | 767 | +31.6% | 0.00% | – |
Q2 2018 | $20,388,000 | -59.5% | 583 | -76.3% | 0.00% | – |
Q1 2018 | $50,373,000 | -26.3% | 2,456 | +1.8% | 0.00% | – |
Q4 2017 | $68,308,000 | +157.5% | 2,412 | +182.8% | 0.00% | – |
Q3 2017 | $26,528,000 | -9.4% | 853 | -7.8% | 0.00% | – |
Q2 2017 | $29,267,000 | +1420.4% | 925 | +988.2% | 0.00% | – |
Q1 2017 | $1,925,000 | -67.9% | 85 | -69.1% | 0.00% | – |
Q4 2016 | $6,003,000 | -42.3% | 275 | -30.4% | 0.00% | – |
Q3 2016 | $10,412,000 | +134.3% | 395 | +75.6% | 0.00% | – |
Q2 2016 | $4,444,000 | – | 225 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |